Boston, MA, USA – April 1, 2024. The 7th Gene Therapy for Rare Disorder 2024 took place in Boston, MA from March 26 to 29, 2024. Dr. Hongxiang Lu, Senior Vice President of Frontera Therapeutics, was invited to participate in the panel discussion on “Gene Drug Manufacturing” and gave a keynote presentation on “Case Studies …
Boston, USA – March 18, 2024 – Frontera Therapeutics, a leading biotechnology company committed to advancing gene therapy drugs to address unmet medical needs worldwide, is delighted to announce its participation in the upcoming 7th Gene Therapy for Rare Disorders 2024 Conference in Boston, USA. Dr. Robert Lu, Senior Vice President of Frontera, has been …
BEDFORD, Mass., and Suzhou, China, January 23, 2024 — Frontera Therapeutics announces that its pioneering AAV gene therapy product, FT-002, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of Inherited Retinal Dystrophies (IRD) caused by RPGR gene variants. About Orphan Drug Designation Orphan Drug Designation, granted …
Hongkong, China, Decemeber 8th, 2023 – Preliminary clinical study results of FT-002, an AAV gene therapy treatment of Frontera Therapeutics, a potential first in class therapy for the treatment of XLRP, were reported at the 16th Asia-Pacific Vitreo-Retina Society, APVRS, 2023). Professor Sui Ruifang from Peking Union Medical College Hospital was invited to participate in …
Beijing, China, Decemeber 3rd, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Frontera Therapeutics) convened a meeting in Beijing on December 3 to conclude the Phase I clinical study of FT-001, and initiate the Phase II clinical study. The meeting was attended by esteemed clinical experts, including Professor Sui Ruifang, Professor Yu …
BEDFORD, Mass., and SHANGHAI, China, Nov 6th, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd (referred to as Frontera) announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has given clearance of the Investigational New Drug (IND) application to begin a clinical trial of an innovative gene therapy drug, FT-002, for …
BEDFORD, Mass., and SHANGHAI, China, July 12, 2023 – An application for an investigational study in human patients with FT-004, an innovative gene therapy drug independently developed by Frontera Biotechnology (Suzhou) Co., Ltd. (hereinafter referred to as “Frontera Biotechnology”), was approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration for …
BEDFORD, Mass., and SHANGHAI, China, June 13th 2023 – Frontera Therapeutics announced another major clinical milestone: FT-003 was successfully dosed for the first patient with Diabetic Macular Edema (DME) in the Ophthalmic Hospital of Tianjin Medical University. This marks the first treatment of gene therapy for this indication in China. Read the original article Li …
Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of 2023 BEDFORD, Mass., and SHANGHAI, China, February 16, 2023 — Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it …
BEDFORD, Mass., and SHANGHAI, China, February 2, 2023 – Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it has dosed the first patient in a clinical trial of its innovative gene therapy product, FT-003, …